How to buy Prothena Corporation stock

Prothena Corporation plc is a biotechnology business based in the US. Prothena Corporation shares (PRTA) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Prothena Corporation

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Prothena Corporation. Find the stock by name or ticker symbol: PRTA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Prothena Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Prothena Corporation, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Prothena Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Prothena Corporation share price

Use our graph to track the performance of PRTA stocks over time.

Prothena Corporation shares at a glance

• Key figures

Information last updated 2021-02-24.

52-week range	USD$7.1 - USD$27.2
50-day moving average	USD$15.2085
200-day moving average	USD$12.7023
Wall St. target price	USD$26.43
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.099

Buy Prothena Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Prothena Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Prothena Corporation plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Prothena Corporation financials

Revenue TTM	USD$853,000
Gross profit TTM	USD$-74,031,000
Return on assets TTM	-18.73%
Return on equity TTM	-48.65%
Profit margin	0%
Book value	$4.609
Market capitalisation	USD$842.7 million

TTM: trailing 12 months

Shorting Prothena Corporation shares

There are currently 674,360 Prothena Corporation shares held short by investors – that's known as Prothena Corporation's "short interest". This figure is 4.4% up from 646,215 last month.

There are a few different ways that this level of interest in shorting Prothena Corporation shares can be evaluated.

Prothena Corporation's "short interest ratio" (SIR)

Prothena Corporation's "short interest ratio" (SIR) is the quantity of Prothena Corporation shares currently shorted divided by the average quantity of Prothena Corporation shares traded daily (recently around 178402.11640212). Prothena Corporation's SIR currently stands at 3.78. In other words for every 100,000 Prothena Corporation shares traded daily on the market, roughly 3780 shares are currently held short.

However Prothena Corporation's short interest can also be evaluated against the total number of Prothena Corporation shares, or, against the total number of tradable Prothena Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Prothena Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Prothena Corporation shares in existence, roughly 20 shares are currently held short) or 0.0221% of the tradable shares (for every 100,000 tradable Prothena Corporation shares, roughly 22 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Prothena Corporation.

Find out more about how you can short Prothena Corporation stock.

Prothena Corporation share price volatility

Over the last 12 months, Prothena Corporation's shares have ranged in value from as little as $7.1 up to $27.2. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Prothena Corporation's is 1.5139. This would suggest that Prothena Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Prothena Corporation overview

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.

Frequently asked questions

• What percentage of Prothena Corporation is owned by insiders or institutions?

  Currently 0.054% of Prothena Corporation shares are held by insiders and 94.695% by institutions.

• When does the fiscal year end for Prothena Corporation?

  Prothena Corporation's fiscal year ends in December.

• Where is Prothena Corporation based?

  Prothena Corporation's address is: 77 Sir John Rogerson?s Quay, Dublin, Ireland, 2

• What is Prothena Corporation's ISIN number?

  Prothena Corporation's international securities identification number is: IE00B91XRN20

• What is Prothena Corporation's CUSIP number?

  Prothena Corporation's Committee on Uniform Securities Identification Procedures number is: G72800108